SHANNON DEERE

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act

Improvements to the 340B drug discount program.

SAVE RARE TREATMENTS TASK FORCE

340B WORKING TABLE

THE DUAL ELIGIBLE COALITION

SAVE RARE TREATMENTS TASK FORCE

340B WORKING TABLE

THE DUAL ELIGIBLE COALITION

SAVE RARE TREATMENTS TASK FORCE

THE DUAL ELIGIBLE COALITION

340B WORKING TABLE

SAVE RARE TREATMENTS TASK FORCE

THE DUAL ELIGIBLE COALITION

340B WORKING TABLE